Mohamed Sherif Salem/LinkedIn
Nov 9, 2025, 11:35
Mohamed Sherif Salem: Anti-Xa Monitoring Did Not Reduce Bleeding or Thromboembolic Events
Mohamed Sherif Salem, Senior Clinical Pharmacist at Andalusia Health Egypt, shared on LinkedIn:
”A 2025 systematic review found that routine anti-factor Xa (anti-Xa) monitoring during therapeutic LMWH therapy led to more dose changes but did not reduce bleeding or thromboembolic events.
Study details:
- Design: Systematic review (4 randomized trials + 44 observational studies; total 48 studies).
- Key dataset: 30 studies ( >3,000 patients) evaluated the relationship between measured anti-Xa activity and bleeding risk.
Findings
- Anti-Xa measurements prompted dose adjustments more frequently than no monitoring.
- There was no reduction in clinical end points (major bleeding or thromboembolism) in monitored versus unmonitored groups.
- Correlation between anti-Xa levels and bleeding (or thrombotic) outcomes was weak or absent in most studies.
Interpretation / practical implications:
- Routine anti-Xa monitoring for patients on therapeutic LMWH cannot be recommended based on current evidence. The data support continuing fixed or weight-based dosing in typical patients.
- Monitoring should be selective: consider anti-Xa measurement in patients where LMWH pharmacokinetics are likely unreliable (examples: significant renal impairment, extremes of body weight, ongoing active bleeding or when clinical management would change based on the result).”
Article: A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins
Authors: Tessa C.C. Jaspers, P. Christian Remmelzwaal, Eefje P.S. Weersink, Karina Meijer, Nakisa Khorsand
Read the full article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2025, 12:37Deise Catamo Vaz Wins Merit Award for Raising Stroke Awareness in Mozambique
-
Nov 9, 2025, 12:34Abena Ntim Asamoah on The Race to End Preventable Maternal Deaths in Africa
-
Nov 9, 2025, 12:34Christian Schulze Shares the CLOSURE AF Insights on Left Atrial Appendage in AFib
-
Nov 9, 2025, 12:33C Michael Gibson and Ulf Landmesser Discuss Insights from CLOSURE-AF trial
-
Nov 9, 2025, 12:32Shakira J Grant on How can AI Transform Outcomes for Patients Who Need It Most?
-
Nov 9, 2025, 12:32Amre Nouh and Ahmed Koriesh on The Future of Post-Stroke Care
-
Nov 9, 2025, 12:31Teagan Prouse and Colleagues on Alternate Functions of Physiological Anticoagulants
-
Nov 9, 2025, 12:30Hema Tallman Congratulates Richard Wilner on Receiving the Sustainability in Life Sciences Award
-
Nov 9, 2025, 12:29Sophie Hordijk on A New Cause of the Hereditary Bleeding Disorder of VWD Type 1